Lipid profile changes associated with changing available formulary statins: removing higher potency agents

Area of Science:

• Cardiovascular Medicine
• Pharmacoeconomics
• Lipid Metabolism

Background:

• Prescription formulary changes can impact medication choices and patient outcomes.
• Statins are crucial for managing dyslipidemia and reducing cardiovascular risk.
• Evaluating the impact of formulary restrictions on lipid-lowering therapy is essential.

Purpose of the Study:

• To assess changes in fasting lipid panels after the removal of high-potency statins from a prescription formulary.
• To determine if formulary adjustments affect key lipoprotein markers associated with cardiovascular health.

Main Methods:

• Retrospective chart review of patients within a managed care plan.
• Comparison of fasting lipid panel results before and after a formulary change impacting statin prescriptions.
• Evaluation of the appropriateness of statin dose equivalency following the formulary adjustment.

Main Results:

• No significant changes were observed in total cholesterol, low-density lipoprotein, or triglyceride levels.
• A significant increase in high-density lipoprotein levels was noted post-formulary change.
• Only 34% of patients received appropriately equipotent or higher-potency statin conversions.

Conclusions:

• Formulary-driven statin substitution did not significantly alter major lipid parameters, apart from an increase in HDL.
• The findings suggest that such formulary changes may not substantially affect surrogate markers of cardiovascular risk.
• Appropriate conversion to equipotent statin doses remains a concern in formulary management.